 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

I-Mab Announces Upcoming Participation at September Conferences I-Mab Announces Upcoming Participation at September Conferences PR Newswire ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 ROCKVILLE, Md...

I-Mab Announces Upcoming Participation at September Conferences

Latest Ratings for IMAB
 DateFirmActionFromTo Nov 2021NeedhamMaintainsBuy Sep 2021HC Wainwright & Co.MaintainsBuy Jun 2021Cantor FitzgeraldMaintainsOverweight
 View More Analyst Ratings for IMAB

 View the Latest Analyst Ratings

read more...

Analyst Ratings for I-MAB

I-Mab Biopharma Non-GAAP EPADS of -$1.05 misses by $0.26, revenue of $2.7M misses by $0.3M

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates PR Newswire ROCKVILLE, Md. and SHANGHAI, Aug. 17, 2023 Significant progress made year-to-date on key clinical assets: Uliledlimab(CD73...

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

I-Mab (IMAB) Q2 2023 Earnings Call Transcript

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023 I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023 PR Newswire ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 ROCKVILLE,Md. and SHANGHAI, Aug. 8, 2023...

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

Key Insights I-Mab's significant retail investors ownership suggests that the key decisions are influenced by...

Painful week for retail investors invested in I-Mab (NASDAQ:IMAB) after 10% drop, institutions also suffered losses

I-Mab Gets New CEO After Long Search. Sale Of The Company Coming Next?

Key Takeaways:
I-Mab has appointed Raj Kannan as its new CEO, filling its top position 18 months after its last top executive quit
The new CEO is an industry veteran who engineered sales of his previous two companies after bringing their first drugs to market, hinting that I-Mab could follow a ...

For the last three days, A.I.dvisor has detected that IMAB's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for IMAB, and traders may view it as a Sell signal for the next month. Traders may consider ...

I-MAB (IMAB, $3.09) Aroon Indicator entered a Downtrend on June 22, 2023.

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.

Watchers	766
52-Wk Low	$1.16
52-Wk High	$7.67

Market Cap	$104.02M
Volume (M)	3,333.00
52-Wk High	$7.67
52-Wk Low	$1.16

IMAB I-Mab - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals